Biodefense and Emerging Infectious Disease Vaccine Studies

生物防御和新发传染病疫苗研究

• 批准号: 10275373
• 负责人: Julie E. Ledgerwood
• 金额: $ 422.89万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10275373
• 关键词: Adult; Avian Influenza; Chikungunya virus; Clinical Trials; DNA; DNA Vaccines; Dose; Ebola; Ebola Vaccines; Emerging Communicable Diseases; Evaluation; Frankfurt-Marburg Syndrome Virus; Generations; Genes; Human; Influenza; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Influenza Hemagglutinin; Intramuscular; Intravenous; Investigation; Malaria; Mission; Phase; Plasmodium falciparum vaccine; Publishing; Regimen; Respiratory Syncytial Virus Vaccines; Respiratory syncytial virus; Route; Safety; Science; Severe Acute Respiratory Syndrome; Uganda; Vaccine Research; Vaccines; West Nile virus; ZIKA; Zika Virus; base; biodefense; chikungunya; first-in-human; immunogenicity; intravenous administration; malaria infection; pandemic disease; pathogen; programs; seasonal influenza; vaccine candidate; vaccine evaluation; vaccine trial

Evaluation of the investigational vaccines in this project are part of the VRC mission related to biodefense and emerging pathogens. Targets include influenza, Ebola, malaria, and others. Further evaluation of vaccine approaches will continue as the VRC develops additional candidate vaccine regimens. Published results from clinical trials have included: VRC 204: Ebola DNA vaccine study: Clin Vaccine Immunol. 2006. 13(11):1267-77 VRC 302: West Nile virus DNA vaccine study: J Infect Dis. 2007. 196(12):1732-40 VRC 301: SARS DNA vaccine study vaccine study. 2008 Nov 25;26(50):6338-43 VRC 303: Second generation West Nile virus DNA vaccine study: J Infect Dis. 2011, May 15;203(10) VRC 205: Second generation Ebola rAd5 vaccine study: Vaccine. 2010 Oct 27 VRC 306: H5N1 gene based prime, inactivated boost vaccine study: Lancet Infect Dis. 2011 Dec;11(12):916-24 VRC 304 and VRC 305: H5 DNA vaccine study and H5 route study: Clin Vaccine Immunol. 2012 Nov; 19(11):1792-7 VRC 310: Follow on H5N1 prime, inactivated boost interval examination study: J Infect Dis. 2013 Aug 1; 208(3):413-7, J Infect Dis. 2013 Aug 1; 208(3):418-22 VRC 312: Dose-escalation with experimental challenge to evaluate intravenous administration of PfSPZ vaccine trial: Science. 2013 Sep 20;341(6152):1359-65 VRC 311: VLP vaccine for Chikungunya virus: Lancet. 2014 Aug 14 VRC 206: Ebola and Marburg vaccine study: J Infect Dis. 2015 Feb 15;211(4):549-57 VRC 207: cAd3-EBO Ebola vaccine study: N Engl J Med. 2014 Nov 26 RV 247: Ebola and Marburg vaccine study in Uganda: Lancet. 2015 Apr 18;385(9977):1545-54 VRC 308: Pandemic H1 DNA vaccine study: PLoS One. 2015 Apr 17;10(4):e0123969 VRC 307 and VRC 309: Seasonal influenza HA DNA followed by TIV boost vaccine study: Contemp Clin Trials. 2015 Aug 11 VRC 314: Experimental controlled human malaria infections to evaluate safety and durability following intravenous and intramuscular administration of PfSPZ vaccine in malaria-naive adults: Nat Med. 2016 Jun;22(6):614-23 VRC 315: Avian influenza H7 DNA and H7N9 MIV vaccine study: NPJ Vaccines. 2017 Jun 1;2:15 VRC 319 and VRC 320: Zika virus DNA vaccine studies: Lancet. 2018 Feb 10;391(10120):552-562 VRC 317: RSV vaccine study: Science. 2019 Aug 2;365(6452):505-509. VRC 704: Phase 2 VLP vaccine for Chikungunya virus: JAMA. 2020 Jul 28;324(4):400.

评估该项目中正在研究的疫苗是生物防御和新出现病原体研究委员会任务的一部分。目标包括流感、埃博拉、疟疾和其他疾病。随着VRC开发更多的候选疫苗方案，将继续对疫苗方法进行进一步评估。